FAQ on TransCode Therapeutics' Phase 1a Trial for RNA-Based Cancer Therapy

What is TTX-MC138?

TTX-MC138 is TransCode Therapeutics’ lead RNA-based therapeutic candidate designed to treat metastatic tumors that overexpress microRNA-10b, a biomarker of metastasis.

How many patients have been dosed in the Phase 1a trial?

As of the announcement, 15 patients have been dosed across four dose levels in the Phase 1a trial of TTX-MC138.

What are the results of the Phase 1a trial so far?

The Safety Review Committee noted no significant toxicities or disease progression to date, with ten patients remaining on study and the longest treated showing stable disease after seven cycles.

What does the early PK/PD data indicate?

Early pharmacokinetic/pharmacodynamic (PK/PD) data confirm target engagement, supporting the advancement to the Phase 1b dose expansion stage.

What is the focus of TransCode Therapeutics?

TransCode Therapeutics is a clinical-stage oncology company focused on treating metastatic disease through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.

Where can I find more information about TransCode Therapeutics?

More information about TransCode Therapeutics can be found in the company’s newsroom at https://ibn.fm/RNAZ.

What is the significance of the Phase 1a trial results?

The results are significant as they show no significant toxicities and stable disease in some patients, indicating potential for TTX-MC138 as a safe and effective treatment for metastatic cancer.

What is the next step after the Phase 1a trial?

The next step is advancing to the Phase 1b dose expansion stage, based on the positive early PK/PD data and safety profile observed in the Phase 1a trial.

How does TTX-MC138 work?

TTX-MC138 is designed to target and treat metastatic tumors that overexpress microRNA-10b, utilizing TransCode’s proprietary TTX nanoparticle platform for effective RNA therapeutic delivery.